Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2022.860158OncologyCorrectionCorrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 PathwayYueDongli12ZhangDaiqun1ShiXiaojuan1LiuShasha1LiAnqi1WangDong12QinGuohui12PingYu1QiaoYamin12ChenXinfeng12WangFeng2ChenRenyin3ZhaoSong4WangLidong5ZhangYi167*1Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China2Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China3Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China4Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China5Henan Key Laboratory for Esophageal Cancer Research and State Key Laboratory for Esophageal Cancer Prevention & Treatment of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China6School of Life Sciences, Zhengzhou University, Zhengzhou, China7Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, China
Edited and reviewed by:Andrew Zloza, Rush University Medical Center, United States
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway By Yue D, Zhang D, Shi X, Liu S, Li A, Wang D, Qin G, Ping Y, Qiao Y, Chen X, Wang F, Chen R, Zhao S, Wang L and Zhang Y (2020). Front. Oncol. 10:311. doi: 10.3389/fonc.2020.00311.esophageal squamous cell carcinoma (ESCC)cancer stem cells (CSCs)CXCR4chloroquine (CQ)STAT3
In the original article, there was a mistake in Figures 3C and 5B as published. In Figure 3C, the representative image of the purity of the two sorted CXCR4 positive/negative subpopulations was inadvertently presented with an incorrect picture. In Figure 5B, incorrect image of western result of t-stat3 and p-stat3 were imported by mistake. The corrected Figures 3 and 5 appears below.
CXCR4 positive cells possessed stem-like properties. (A) The CXCR4 expression was detected by real time PCR in 1 immortalized esophageal cell line (Het-1a) and 4 ESCC cell lines. (B) The expression analysis of CXCR4 was detected by flow cytometry. (C) The purity of sorted EC109 cells with or without CXCR4 expression. (D) The expressio analysis of CXCR4 was detected by real time PCR. (E) The expression analysis of stemness-related transcription factors (SOX9, OCT4, LIN28, and NANOG) was detected by real time PCR. (F) Cell survival rate was tested by CCK-8 method. *P < 0.05, **P < 0.01, and ***P < 0.001.
Chloroquine targeted CXCR4-positive ESCC cells via STAT3. (A) The expression of CXCR4 was analyzed by flow cytometry. (B) The activity of pSTAT3 and tSTAT3 were measured by western blotting in ESCC cells with or without CQ treatment (5µM). (C) The expression of CXCR4 was analyzed by flow cytometry in ESCC cells with or without STAT3 inhibitor (S3I-201, Sigma, USA) treatment. (D) The expression analysis of ATG7 and BECN1 was detected by real time PCR in ESCC cells with or without CQ treatment (5µM). (E) The expression of CXCR4 was analyzed by flow cytometry in ESCC cells after ATG7 or BECN1 knockdown. *P < 0.05.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.